鼻内糖皮质激素是治疗过敏性鼻炎（AR）最有效的一线药物之一，其对AR患者的所有鼻部症状包括喷嚏、流涕、鼻痒和鼻塞均有显著改善作用。近年来国内外指南为SAR临床诊断和治疗提供了循证医学证据和指导；鼻内糖皮质激素作为SAR一线治疗得到国内外指南的一致推荐，其中布地奈德显著改善鼻部症状、眼部症状以及睡眠问题，可作为预防性治疗药物改善SAR患者症状。
Intranasal corticosteroid is one of the most effective first-line drugs for treatment of allergic rhinitis (AR). It can significantly relieve the nasal symptoms of AR patients, including sneezing, running nose, itching and congestion. For years, domestic and overseas guidelines have provided proof and guidance of evidence-based medicine for the clinical diagnosis and treatment of SAR; intranasal corticosteroid, as the first-line treatment of SAR, has been unanimously recommended in domestic and overseas guidelines. Specifically, Budesonide significantly improves nasal symptoms, eye symptoms and sleep problems, and can be used as the preventive drug therapy to improve the symptoms of SAR patients.
 
对于伴息肉的慢性鼻窦炎（CRSwNP），指南建议原则上先采用至少3个月规范药物治疗，效果不满意再进行手术。慢性鼻病具有显著异质性，其中嗜酸性粒细胞型鼻息肉复发率接近99%，且往往伴有系统性炎症。对于这种分型，更适合使用鼻用糖皮质激素进行治疗，而手术只是治疗中的辅助手段，持续的抗炎治疗是核心。
For CRS with nasal polyps (CRSwNP), the guidelines recommend an at least 3-month standardized drug treatment in principle before operation which is only conducted when there is no satisfactory effect. Chronic rhinopathy features significant heterogeneity. Among them, eosinophilic nasal polyp (ENP) has a recurrence rate approaching 99%, and always features systematic inflammation, which makes it more suitable to be treated with intranasal corticosteroids. In addition, operation is just a supplementary means to treatment, and continuous anti-inflammatory treatment is at the core.
 
近期的流行病学和临床研究提示，空气污染是影响过敏性鼻炎患病率的重要环境因素，会加重过敏性鼻炎症状，诱导过敏性鼻炎发生。目前治疗空气污染相关鼻炎药物的证据匮乏，在强生集团资助下，6个中心联合完成了《布地奈德鼻喷雾剂治疗空气严重污染期间鼻炎的一项IV期随机、双盲、安慰剂对照、多中心研究》，证实布地奈德是目前第一个经过临床研究证实对空气污染相关的鼻炎有效的鼻用激素，可显著改善患者在空气污染期间的鼻部整体状况，尤其是鼻痒/喷嚏症状。
Recent epidemiologic and clinical researches show that, air pollution is a key environmental factor affecting the prevalence rate of AR, and can worsen the symptoms of AR and induce the occurrence of AR. Currently there is scarce evidence for drugs treating air pollution-related rhinitis. Thanks to the financial aid of Johnson & Johnson, six centers have jointly completed a Phase IV, Randomized, Double-blind, Placebo-controlled and Multi-center Study on Treating Rhinitis with Budesonide Nasal Spray During Severe Air Pollution, confirming that Budesonide is the first effective intranasal corticosteroid for air pollution-related rhinitis verified by clinical research and can evidently improve the general nasal conditions of the patients during air pollution, especially itching/sneezing symptoms.